Yet, even in this exuberant wilderness, a few blooms offer not only visual appeal but a subtle, perfumed promise of income. We shall, with a suitably detached curiosity, examine two such instances: Enterprise Products Partners and Bristol Myers Squibb. Consider them, if you will, as particularly well-preserved butterflies pinned for our inspection.
Now, everyone’s been assuming Nvidia, the current darling of the AI boom, would be the primary beneficiary. And they will be, to a degree. Amazon will be loading up on Nvidia’s GPUs, those little silicon workhorses that power so much of the digital world. But something rather interesting is happening. Amazon, it turns out, isn’t content to simply buy the future; it wants to build it. And that means chips of its own.
IonQ, for instance, briefly touched a peak of $84.64. A sum, one might observe, sufficient to purchase a respectable collection of samovars. Yet, as of late, the stock has retreated, surrendering 24% of its fleeting glory. A cautionary tale, perhaps, about the perils of mistaking speculation for substance.
Kanen, you see, now owns a substantial 20.52% slice of Compass, a firm valued at $329.38 million. Which, if you consider the sheer number of bricks and mortar involved in the real estate business, is a surprisingly small number of gold coins. They’ve clearly decided that Compass isn’t just building houses; they’re building something…different. Something involving algorithms and digital maps and, if I’m not mistaken, a worrying amount of data.1
Novo Nordisk, bless its diligent heart, was the first to stumble upon the elixir of weight loss in injectable form. A pioneering achievement, quickly overshadowed by the superior marketing of Eli Lilly (LLY +0.39%) and, let’s be honest, a slightly more potent concoction. Compounded versions of Wegovy, a testament to human ingenuity and the relentless pursuit of profit, began to appear. A chaotic scene, really. And now, Mounjaro and Zepbound reign supreme. A predictable outcome, one might say, in a world where perception is often more valuable than reality.
I’ve landed on two companies, not because I’m particularly optimistic about the future, but because they seem… less terrible than most. Broadcom and IBM. I’m not suggesting you remortgage your house, of course. But a few thousand dollars? It could be worse. It could be spent on another limited-edition porcelain cat.
Bandwidth reported earnings, which, as far as earnings reports go, were…earnings. A bit of a miss on revenue, a little nudge above on profit. The usual dance. Honestly, I find these quarterly pronouncements exhausting. It’s like everyone’s pretending to be surprised by things they already knew six weeks ago. Investors, however, latched onto the 2026 guidance. An acceleration in revenue, margin expansion… the usual promises. It’s the hope that kills you, as my grandmother used to say, right before she’d buy another set of collectible thimbles.
But fear not, for they’ve decided to do a bit of dividing. A splitting, if you will. A 25-for-1 split, to be precise. It’s like taking a whole apple pie and slicing it into twenty-five smaller pieces. You still have the same pie, mind you, but now more folks can get a slice without needing a ladder.
Analysts, those appointed arbiters of potentiality, now project a valuation for Viking Therapeutics—a company whose existence is, in essence, a protracted experiment—reaching, in some estimations, $125 per share. This figure, exceeding the current price by a margin that borders on the fantastical, suggests a conviction bordering on delusion. One wonders, naturally, if these projections are based on careful calculation, or merely the result of a systemic error in the forecasting protocols. The ticker, VKTX, appears to be suspended in a peculiar state of anticipation, awaiting a judgment it may never fully comprehend.
As of the hour of two and twenty minutes past noon, the shares of Wheels Up have fallen by nearly twelve percent. A significant tremor in the marketplace, yet merely a ripple in the vast ocean of capital. Still, it compels one to consider the human dramas unfolding within this single company – the hopes of the founders, the calculations of the investors, and the quiet anxieties of those who have placed their faith – and their fortunes – in this venture.